InflaRx N.V. (IFRX) Surges to Record High, Is Now Top Performer

April 17, 2018 - By James Guidry

The stock of InflaRx N.V. (NASDAQ:IFRX) reached all time high today, Apr, 17 and still has $39.66 target or 4.00 % above today’s $38.13 share price. This indicates more upside for the $892.66 million company. This technical setup was reported by Barchart.com. If the $39.66 PT is reached, the company will be worth $35.71M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 9.70% or $3.37 during the last trading session, reaching $38.13. About 73,437 shares traded or 35.25% up from the average. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $892.66 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: